Active Ingredient History
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia. It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amenorrhea (Phase 2)
Diabetes Mellitus (Phase 3)
Fasting (Phase 1/Phase 2)
HIV-Associated Lipodystrophy Syndrome (Phase 2)
HIV Infections (Phase 2)
Hyperlipidemias (Phase 3)
Insulin Resistance (Phase 2)
Lipodystrophy, Congenital Generalized (Phase 4)
Lipodystrophy, Familial Partial (Phase 2)
Lipomatosis, Multiple Symmetrical (Phase 1)
Metabolic Syndrome (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 2)
Obesity (Phase 2)
Overweight (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
